Checkmate Pharmaceuticals, Inc.
CMPIDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted in 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Checkmate Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- −6 vs. Q3 2021
- Shares held
- 16.1M
- −146.5K (−0.9%) vs. Q3 2021
- Total value
- $46.3M
- −$18.3M (−28.4%) vs. Q3 2021
- New holders
- 1
- 5 more added
- Sold out
- 7
- 6 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 26 | $54.8M |
| Q4 2021 | 25 | $46.3M |
| Q3 2021 | 31 | $64.6M |
| Q2 2021 | 34 | $97.3M |
| Q1 2021 | 37 | $202.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Checkmate Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| venBio Partners LLC | 3,673,374 | $10.5M | 1.90% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 3,606,707 | $10.4M | 0.66% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,170,100 | $6.23M | 0.29% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 1,501,716 | $4.31M | 1.08% | 00.0% | Unchanged |
| Omega Fund Management, LLC | 1,335,050 | $3.83M | 0.54% | 00.0% | Unchanged |
| Clough Capital Partners L P | 1,306,626 | $3.75M | 0.25% | −260,700−16.6% | Reduced |
| FMR LLC | 967,226 | $2.78M | 0.00% | +1,000+0.1% | Added |
| Vanguard Group Inc | 579,861 | $1.66M | 0.00% | +243,274+72.3% | Added |
| Sectoral Asset Management Inc | 541,766 | $1.55M | 0.23% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 106,500 | $306.0K | 0.01% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 93,334 | $268.0K | 0.00% | −26,581−22.2% | Reduced |
| RBF Capital, LLC | 68,034 | $195.0K | 0.01% | −800−1.2% | Reduced |
| BlackRock Inc. | 52,369 | $151.0K | 0.00% | +575+1.1% | Added |
| Geode Capital Management, LLC | 40,260 | $115.0K | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 30,092 | $87.0K | 0.00% | +10,092+50.5% | Added |
| Cambridge Trust Co | 24,609 | $71.0K | 0.00% | −24,609−50.0% | Reduced |
| State Street Corp | 11,087 | $32.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 10,633 | $31.0K | 0.00% | +10,633 | New |
| Morgan Stanley | 4,075 | $12.0K | 0.00% | −45−1.1% | Reduced |
| US Bancorp | 2,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,112 | $4.00K | 0.00% | −2,258−67.0% | Reduced |
| UBS Group AG | 1,105 | $4.00K | 0.00% | +922+503.8% | Added |
| Johnson Midwest Financial, LLC | 200 | $1.00K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 168 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 33 | $0 | 0.00% | 00.0% | Unchanged |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −36,511−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −25,870−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −18,298−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −10,667−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,426−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −185−100.0% | Sold out |